Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020Cited by 766
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung CancerJustin F. Gainor, Jennifer Peterson, Kylie Prutisto-Chang et al.|Clinical Cancer Research|2021Cited by 137
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLCW. Marston Linehan, Gregory J. Riely, Viola W. Zhu et al.|Journal of Thoracic Oncology|2018Cited by 82
PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung CancersAlexander Drilon, Kristoffer Staal Rohrberg, Geoffrey R. Oxnard et al.|Journal of Thoracic Oncology|2019Cited by 81
Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancerMark M. Awad, Andrew J. Aguirre, Shengwu Liu et al.|Cancer Research|2021Cited by 12